Expertise in
29
conditions

Dr. Frederick N. Lansigan

Hematology
D-H Dermatology
18 Old Etna Rd, 
Lebanon, NH 
Offers Telehealth
Expertise in
29
conditions
D-H Dermatology
18 Old Etna Rd, 
Lebanon, NH 

Overview

Frederick Lansigan is a Hematologist practicing medicine in Lebanon, New Hampshire.

Dr. Lansigan is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), Cutaneous T-Cell Lymphoma (CTCL), Bone Marrow Aspiration, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 81 peer reviewed articles and participating in 11 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in NH

Hospital Affiliations

Mary Hitchcock Memorial Hospital
Cheshire Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MVP Health
  • EPO
  • PPO
NH Healthy Families
  • EPO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

D-H Dermatology
18 Old Etna Rd, Lebanon, NH 03766
Other Locations
Mary Hitchcock Memorial Hospital
1 Medical Center Dr, Lebanon, NH 03756

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Drug, Biological, Procedure
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
Study Phase: Phase 2/Phase 3
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Enrollment Status: Active_not_recruiting
Publish Date: July 17, 2026
Intervention Type: Biological, Procedure
Study Drug: Rituximab
Study Phase: Phase 3
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: July 08, 2026
Intervention Type: Drug, Biological, Procedure
Study Drugs: Bendamustine Hydrochloride, Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Obinutuzumab, Prednisone, Umbralisib, Vincristine Sulfate
Study Phase: Phase 2
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2026
Intervention Type: Drug, Biological
Study Drugs: Rituximab, Bendamustine Hydrochloride, Bortezomib, Lenalidomide
Study Phase: Phase 2
A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination With Nivolumab in Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination With Nivolumab in Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: May 12, 2026
Intervention Type: Biological, Drug
Study Drugs: Nivolumab, Varlilumab
Study Phase: Phase 2
Phase 2 Study of Copanlisib in Combination With Nivolumab in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma
Phase 2 Study of Copanlisib in Combination With Nivolumab in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma
Enrollment Status: Completed
Publish Date: March 03, 2025
Intervention Type: Biological, Drug
Study Drugs: Copanlisib Hydrochloride, Nivolumab
Study Phase: Phase 2
Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide (R2-ICE) in Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide (R2-ICE) in Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Unknown
Publish Date: July 01, 2024
Intervention Type: Biological, Drug, Other
Study Drugs: Carboplatin, Etoposide, Ifosfamide, Lenalidomide, Rituximab
Study Phase: Phase 1/Phase 2
Phase 2 Trial of the Heat Shock Protein-90 (Hsp90) Inhibitor AT13387 (Onalespib) in Patients With Relapsed/Refractory ALK+ ALCL, Mantle Cell Lymphoma, and BCL6+ DLBCL
Phase 2 Trial of the Heat Shock Protein-90 (Hsp90) Inhibitor AT13387 (Onalespib) in Patients With Relapsed/Refractory ALK+ ALCL, Mantle Cell Lymphoma, and BCL6+ DLBCL
Enrollment Status: Terminated
Publish Date: September 13, 2022
Intervention Type: Drug
Study Drug: Onalespib
Study Phase: Phase 2
SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype
SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype
Enrollment Status: Terminated
Publish Date: April 08, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

81 Total Publications

Localized radiation therapy provides more durable disease control than topical steroids in stage IA mycosis fungoides.
Localized radiation therapy provides more durable disease control than topical steroids in stage IA mycosis fungoides.
Journal: Journal of the American Academy of Dermatology
Published: March 14, 2026
Similar Doctors
Expertise in
10
conditions
Expertise in
10
conditions
Referral may be required

Mary Hitchcock Memorial Hospital

1 Medical Center Dr, 
Lebanon, NH 
 (2.1 miles away)
603-650-6763
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Monic Drescher is a Hematologist practicing medicine in Lebanon, New Hampshire. Dr. Drescher is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Venous Thromboembolism (VTE), Shwartzman Phenomenon, Hemophilia B, Pulmonary Embolism, and Bone Marrow Aspiration.

Expertise in
9
conditions
Expertise in
9
conditions
Referral may be required

Mary Hitchcock Memorial Hospital

1 Medical Center Dr, 
Lebanon, NH 
 (2.1 miles away)
603-650-6763
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Deborah Ornstein is a Hematologist practicing medicine in Lebanon, New Hampshire. Dr. Ornstein is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Hemophilia B, Hemophilic Arthropathy, Hemophilia A, and Deep Vein Thrombosis.

Expertise in
10
conditions
Dr. Daniel J. Zinn
Hematology | Oncology
Expertise in
10
conditions
Dr. Daniel J. Zinn
Hematology | Oncology
Referral may be required

Mary Hitchcock Memorial Hospital

1 Medical Center Dr, 
Lebanon, NH 
 (2.1 miles away)
603-650-5541
Languages Spoken:
English
See accepted insurances

Daniel Zinn is a Hematologist and an Oncologist practicing medicine in Lebanon, New Hampshire. Dr. Zinn is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Langerhans Cell Histiocytosis, Reticulohistiocytoma, Histiocytosis, and Multicentric Reticulohistiocytosis.

Frequently Asked Questions about Dr. Frederick N. Lansigan

How do I make an appointment with Dr. Frederick N. Lansigan?

You can book an appointment with Dr. Frederick N. Lansigan by calling their office at 603-650-4000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Frederick N. Lansigan a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Frederick N. Lansigan is classified as an Elite expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Frederick N. Lansigan specialize in?

While Dr. Frederick N. Lansigan is a Hematology, they have specific expertise in Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), and Cutaneous T-Cell Lymphoma (CTCL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Frederick N. Lansigan participate in research or clinical trials?

Yes. Dr. Frederick N. Lansigan has published 81 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Dr. Frederick N. Lansigan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Frederick N. Lansigan accept my insurance?

Dr. Frederick N. Lansigan accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 603-650-4000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lansigan's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 14 Advanced Conditions
View All 40 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile